NEW YORK, Sept. 14, 2016 /PRNewswire/ -- Harwood
Feffer LLP (www.hfesq.com) is investigating potential claims
against the board of directors of Vitae Pharmaceuticals, Inc.
("Vitae" or the "Company") (NASDAQ: VTAE) concerning the proposed
acquisition of the Company by Allergan plc ("Allergan").
Under the terms of the offer, Allergan would acquire Vitae in a
transaction valued at approximately $640
million. Pursuant to the deal, Vitae stockholders will
receive $21.00 in cash per share of
Vitae owned.
Our investigation concerns whether the Vitae board of directors
is fulfilling its fiduciary duties, maximizing the value of the
Company, disclosing all material benefits and costs, and obtaining
full and fair consideration for Company stockholders.
If you own Vitae shares and wish to discuss this matter with us,
or have any questions concerning your rights and interests with
regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Craig Lowther
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the
firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
Logo -
http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-vitae-pharmaceuticals-inc-300328347.html
SOURCE Harwood Feffer LLP
